A Study of Patients With HER2-Positive Metastatic Breast Cancer

Genentech, Inc.1,000 enrolled

Overview

This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Breast Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed Informed Consent document (unless the IRB has granted a waiver of consent) * Signed Authorization for the Use and Disclosure of Health Information document * HER2-positive breast cancer * Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment * Availability of cancer-specific historical data points in the patient's medical records Exclusion Criteria: * There are no exclusion criteria for participation in this trial

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.